Clinical Trial Update: Effects of Enavogliflozin on Coronary Microvascular and Cardiac Function in Obesity [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating enavogliflozin effects on coronary microvascular and cardiac function in obesity; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Type 2 Diabetes Mellitus

Drugs mentioned

• Enavogliflozin (enavogliflozin)

Snippet

Sponsor: Korea University Anam Hospital | Conditions: Obesity and Type 2 Diabetes | Phase 4 | Status: RECRUITING